Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2015-11-27 Major Shareholding Noti…
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
SC 13G
Major Shareholding Notification
2015-11-27 English
EMPERY ASSET MANAGEMENT, LP
Major Shareholding Notification
2015-11-24 English
SABBY 13G GALT 11.23.15
Major Shareholding Notification
2015-11-23 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 19, 2015, by Galectin Therapeutics Inc. It reports the entry into a material definitive agreement related to a securities purchase agreement for a registered direct offering of common stock and warrants. The document details the terms of the offering, the securities involved, and related agreements. It also includes exhibits such as the purchase agreement, placement agency agreement, and press release. The content focuses on a financing transaction and capital raising activity. There are no financial statements or quarterly/yearly financial results presented, nor is it an announcement of voting results, management changes, or legal proceedings. The primary subject is the update on the company's capital raising and financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (7840 characters) supports it being a full report rather than a brief announcement or certification.
2015-11-20 English
FILED PURSUANT TO RULE 424(B)(5)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering. It details the terms of the offering, including the number of shares, pricing, placement agent fees, and use of proceeds. The document is a formal disclosure related to a capital raising event, specifically a public offering of common stock. It is not a financial report, earnings release, or management discussion, but rather a detailed capital/financing update describing the securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback.
2015-11-20 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2015, by Galectin Therapeutics Inc. It announces the results of operations and financial condition for the three and nine months ended September 30, 2015, referencing a press release attached as Exhibit 99.1. The text explicitly states that the information is being furnished under Item 2.02 of Form 8-K, which is typically used for current reports including earnings releases. The document is short (3798 characters) and primarily serves as an announcement of financial results rather than a full detailed report. The presence of a press release announcing quarterly results aligns with the definition of an Earnings Release (ER). Therefore, the document should be classified as an Earnings Release (ER).
2015-11-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.